AzTrials
AzTrials

Esophageal CancerISCONNCT03896399

Laparoscopic Ischemic Conditioning Prior to Esophagectomy

A study testing Laparoscopic ischemic conditioning followed by esophagectomy in people with Esophageal Cancer, run by UMC Utrecht at 2 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a two center phase II prospective single-arm safety and feasibility trial for 20 patients with resectable esophageal carcinoma with an increased risk for anastomotic leakage, as based upon UCS and NASCET calcification scores on pre-op CT-scan. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Esophageal Cancer
What is being tested?
Laparoscopic ischemic conditioning followed by esophagectomy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
22 participants
Where
2 sitesin 2 countries
Study dates
11 Nov 2019to 2 May 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histologically proven adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ)
  • Planned to undergo transthoracic esophagectomy or transhiatal esophagectomy
  • Preoperative computed tomography (CT)
  • Vascular arterial changes: "major calcifications" of the thoracic aorta according to the "Uniform calcification score" (UCS) and or a stenosis of the celiac axis according to the "modified NASCET score". (Appendix 1 and 2) (7,17)
  • ASA I-III
  • European Clinical Oncology Group (ECOG) performance status of 0,1 or 2
  • Age > 17
  • Written informed consent

Who cannot join

  • Not able to undergo study treatment.
  • Metastatic disease (M1)

Trial locations and contacts

2 sites in 2 countries.

2 sites in 2 countries

Germany1 site
  • University Hospital of Cologne

    Cologne, North Rhine-Westphalia, 50937

Other trials in Germany

Netherlands1 site
  • University Medical Center Utrecht

    Utrecht, 3584 CX

Other trials in Netherlands

About this study

Official title: Laparoscopic Ischemic Conditioning Prior to Esophagectomy in Patients With Esophageal Cancer and Arterial Calcifications

This is a two center phase II prospective single-arm safety and feasibility trial for 20 patients with resectable esophageal carcinoma with an increased risk for anastomotic leakage, as based upon UCS and NASCET calcification scores on pre-op CT-scan. In these patients, laparoscopic ischemic conditioning is performed 12-18 days before an Ivor-Lewis esophagectomy. The primary outcome is all complications grade 2 and higher (Clavien-Dindo classification) occurring during or after the laparoscopic ischemic conditioning. Secondary outcomes are complications after the esophagectomy, and the induction of angiogenesis by biomarkers of microcirculation and redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography.

Read the detailed description

Rationale:

Anastomotic leakage is the most important surgical complication following esophagectomy for esophageal cancer, leading to increased morbidity and mortality. A major cause of leakage is impaired healing due to ischemia of the gastric tube that is used for reconstruction of the gastrointestinal tract. Calcifications of the aorta or stenosis of the celiac trunk on pre-operative CT scan have been shown to be associated with an increased risk of anastomotic leakage. So far, no individualized treatment has been initiated for this selected group of patients. Laparoscopic ischemic conditioning (ISCON) of the gastric tube aims to increase perfusion at the anastomotic site by redistribution of the gastric blood flow and/or induction of angiogenesis. This is achieved by occlusion of the supplying gastric arteries except for the right gastroepiploic artery during a separate intervention prior to esophagectomy. Of note, these arteries would also be occluded during conventional esophagectomy, but with laparoscopic ISCON they are occluded at an earlier moment in time during a separate intervention. Retrospective studies have demonstrated the safety of this technique. Prospective studies have not yet been performed.

Primary objective:

Assess the safety and feasibility of laparoscopic ISCON 12-18 days prior to esophagectomy for esophageal cancer in patients with arterial calcifications.

Study design:

Two center phase II prospective single-arm safety and feasibility trial.

Study population:

Patients with resectable esophageal carcinoma (cT1-4a, N0-3, M0) with "major calcifications" of the thoracic aorta (UCS) and any additional calcification or stenosis of the celiac axis (modified NASCET score) on preoperative CT scan, who are planned to undergo esophagectomy.

Intervention:

Laparoscopic ISCON followed by esophagectomy after an interval of 12-18 days.

Primary outcome:

all complications grade 2 and higher (Clavien-Dindo classification) occurring during or after operation 1 (laparoscopic ISCON) and before operation 2 (esophagectomy).

Secondary outcomes:

secondary outcomes with regard to operation 1 (laparoscopic ISCON) are the duration of the procedure, blood loss, day of discharge postoperatively and grade 1 complications. Secondary outcomes with regard to operation 2 (esophagectomy) are anastomotic leakage rate, all other grade 3b or higher complications and 30 day mortality. Further secondary endpoints are the induction of angiogenesis by biomarkers of microcirculation and redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

the additional burden for the patient consists of an extra operation of approximately 40 minutes during which laparoscopic ISCON will be performed, prior to the planned esophagectomy. We would classify the current study as medium risk. Potential benefits in comparison to current standard treatment are a reduced risk of anastomotic leakage and severity of anastomotic leakage. Potential risks are complications following operation 1 (laparoscopic ISCON). Mainly, based upon prior experience, we expect gastroparesis to occur in 25% of patients. Patients with gastroparesis have an increased risk of aspiration and will require a stomach emptying by nasogastric tube and nasojejunal tube feeding till the performance of operating 2 (esophagectomy).

Being tested
Laparoscopic ischemic conditioning followed by esophagectomy
Keywords
Esophageal Cancer, Esophagectomy, Ischemic conditioning
Medical subject headings
Esophageal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Laparoscopic ischemic conditioning followed by esophagectomyProcedure or surgery

    All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.

Study groups in NCT03896399
Study groupRoleWhat they receive
Laparoscopic ischemic conditioning followed by esophagectomyExperimentalAll included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
Receives: Procedure: Laparoscopic ischemic conditioning followed by esophagectomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants with a grade 2 or higher complication after laparoscopic ischemic conditioning

    Complications grade 2 and higher (Clavien-Dindo classification)

    Measured: Occuring after operation 1(laparosocpic ISCON), but before operation 2 (esophagectomy). This time-frame is usually 13-15 days.

Secondary outcomes (10)
  1. Number of participants with a grade 1 complication after operation 1 (laparoscopic ISCON)

    Grade 1 complications after operation 1 (laparoscopic ISCON)

    Measured: Occuring after operation 1(laparosocpic ISCON), but before operation 2 (esophagectomy). This time-frame is usually 13-15 days.

  2. Duration of operation 1 (laparoscopic ISCON)

    Duration of operation 1 (laparoscopic ISCON)

    Measured: During operation 1

  3. Bloodloss during operation 1 (laparoscopic ISCON)

    Bloodloss during operation 1 (laparoscopic ISCON)

    Measured: During operation 1

  4. Day of discharge after operation 1 (laparoscopic ISCON)

    Day of discharge after operation 1 (laparoscopic ISCON)

    Measured: After operation 1, usually on the third post-operative day

  5. Number of participants with anastomotic leakage after operation 2 (esophagectomy)

    Anastomotic leakage after operation 2 (esophagectomy)

    Measured: Within 30 days after operation 2

  6. Number of participants with grade 3b or higher complications after operation 2 (esophagectomy)

    Grade 3b (Clavien-Dindo classification) or higher complications after operation 2 (esophagectomy)

    Measured: Within 30 days after operation 2

  7. Number of participants with 30 day mortality after operation 2 (esophagectomy)

    30 day mortality after operation 2 (esophagectomy)

    Measured: Within 30 days after operation 2

  8. Induction of angiogenesis in tissue

    Paraffin embedded sections (10µm) will be stained by immunohistochemistry against CD31 (vessel density) or smooth-muscle-actin positive pericytes to characterize vascularity

    Measured: Biopsies are taken at the start, or within 24 hours of operation 1 and operation 2. In addition, the anastomoc donut or tip of gastric tube is collected during operation 2 (esophagectomy) after formation of the anastomosis.

  9. Induction of angiogenesis by biomarkers of microcirculation

    A cytokine profile will be measured in the peripheral blood, consisting of VEGF, IL-8, IL-6, TNF-alpha and Ang-2

    Measured: Peripheral blood is taken at the start, or within 24 hours of operation 1

  10. Redistribution of blood flow by measurement of indocyanine green (ICG) fluorescence angiography

    Redistribution of blood flow by measurement of indocyanine green (ICG)

    Measured: During operation 1 and during operation 2 (esophagectomy)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Apr 2019
  2. Study start11 Nov 2019
  3. Primary completion2 May 2022
  4. Study completion2 May 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
22 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03896399
Sponsor's protocol ID
NL67819.041.18
Acronym
ISCON
Status last verified
May 2022
First submitted
20 Mar 2019
Last updated
19 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: This will be published

Publications

  • Veen AV, Schiffmann LM, de Groot EM, Bartella I, de Jong PA, Borggreve AS, Brosens LAA, Santos DPD, Fuchs H, Ruurda JP, Bruns CJ, van Hillegersberg R, Schroder W. The ISCON-trial protocol: laparoscopic ischemic conditioning prior to esophagectomy in patients with esophageal cancer and arterial calcifications. BMC Cancer. 2022 Feb 5;22(1):144. doi: 10.1186/s12885-022-09231-x.

    PubMed 35123419

Questions about this trial

What is this clinical trial studying?

A study testing Laparoscopic ischemic conditioning followed by esophagectomy in people with Esophageal Cancer, run by UMC Utrecht at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany, Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants with a grade 2 or higher complication after laparoscopic ischemic conditioning (time frame: Occuring after operation 1(laparosocpic ISCON), but before operation 2 (esophagectomy). This time-frame is usually 13-15 days.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03896399, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in